Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

EVT801

Small molecule · Inhibitor of vascular endothelial growth factor receptor 3 (FLT4) · developed by Kazia Therapeutics

Phase 1 Most advanced trial (none active)
KZIA Developer
1 Registered trials

What is EVT801?

EVT801 is an orally bioavailable small molecule that binds and inhibits the tyrosine kinase of VEGFR3 (FLT4), a receptor expressed on lymphatic endothelial cells and in many solid and hematologic malignancies. By blocking VEGFR3 it is intended to inhibit tumor angiogenesis and may also reduce circulating myeloid-derived suppressor cells. It is being studied in adult patients with solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
vascular endothelial growth factor receptor 3 (FLT4)
Mechanism
Inhibitor of vascular endothelial growth factor receptor 3 (FLT4)
Pathways
angiogenesis, myeloid-derived suppressor cell reduction
Therapy area
Oncology
Developer
Kazia Therapeutics Limited (KZIA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05114668 Phase 1 Solid Tumor, Adult Completed KZIA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Solid Tumor, Adult

Other drugs acting on FLT4

More from Kazia Therapeutics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KZIA page.

Follow KZIA, the company behind EVT801

See KZIA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KZIA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.